Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Dendreon
With that in mind, let's take a closer look at Dendreon's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Seattle (1992)|
|Market Cap||$1.1 billion|
|Trailing-12-Month Revenue||$396.7 million|
|Management||CEO John Johnson (since February 2012)
CFO Gregory Schiffman (since December 2006)
|Return on Capital (average, past 3 years)||(24.7%)|
|Cash/Debt||$497.5 million / $573.8 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 17% of the 1,623 members who have rated Dendreon believe the stock will underperform the S&P 500 going forward.
I can't find any fundamentals that would suggest Dendreon share price should increase from here. Although it's Provenge is a worthy achievement, as expected it couldn't productize it and it never got the buyout it sought. One trick pony with a drug that's expensive, difficult to manufacture and difficult to get doctors to prescribe. Burn rate continues with no end in sight.
If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've compiled a special free report for investors called "Discover the Next Rule-Breaking Multibagger," which uncovers another growth play with big potential. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.